Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of cemiplimab versus investigator's choice chemotherapy in platinum-refractory recurrent or metastatic cervical cancer
2017-000350-19Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cemiplimab in Cervical Cancer (CC) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Overall survival. Started Sep 2017; status: completed.
02
Drugs
cemiplimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2017-000350-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000350-19.